h-dmt-tic-gly-nh-bzl has been researched along with Pain* in 1 studies
1 other study(ies) available for h-dmt-tic-gly-nh-bzl and Pain
Article | Year |
---|---|
In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.
Targeting more than one opioid receptor type simultaneously may have analgesic advantages in reducing side-effects. We have evaluated the mixed μ opioid receptor agonist/ δ opioid receptor antagonist UFP-505 in vitro and in vivo.. We measured receptor density and function in single μ, δ and μ /δ receptor double expression systems. GTPγ. UFP-505 bound to μ receptors with full agonist activity and to δ receptors as a low efficacy partial agonist At μ, but not δ receptors, UFP-505 binding recruited arrestin. Unlike morphine, UFP-505 treatment internalized μ receptors and there was some evidence for internalization of δ receptors. Similar data were obtained in a μ /δ receptor double expression system. In rats, acute UFP-505 or morphine, injected intrathecally, was antinociceptive. In tissues harvested from these experiments, μ and δ receptor density was decreased after UFP-505 but not morphine treatment, in agreement with in vitro data. Both morphine and UFP-505 induced significant tolerance.. In this study, UFP-505 behaved as a full agonist at μ receptors with variable activity at δ receptors. This bifunctional compound was antinociceptive in rats after intrathecal administration. In this model, dual targeting provided no advantages in terms of tolerance liability.. This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc. Topics: Analgesics; Animals; CHO Cells; Cricetulus; Injections, Spinal; Ligands; Male; Oligopeptides; Pain; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu | 2018 |